Medindia LOGIN REGISTER
Medindia

Highly Compatible COVID-19 Vaccine of India: Launched

by Karishma Abhishek on Apr 24 2022 11:59 PM

Indian Institute of Science in Bengaluru and biotech start-up Mynvax develops a new heat-tolerant COVID-19 vaccine that shows a strong antibody response against COVID variants.

Highly Compatible COVID-19 Vaccine of India: Launched
India¡¦s new heat-tolerant COVID-19 vaccine developed by the Indian Institute of Science in Bengaluru and biotech start-up Mynvax has shown a strong antibody response against COVID variants including Delta and Omicron, as per a study on mice, published in the peer-reviewed journal Viruses.
The heat-tolerant COVID-19 vaccine candidate can be stored at 37 degrees Celsius for four weeks and at 100 degrees Celsius for up to 90 minutes.

The vaccine candidate uses a part of the viral spike protein called the receptor-binding domain that allows the virus to connect with the host cell to infect it.

The study assessed vaccinated mice sera for efficacy against key coronavirus variants, including Delta and Omicron.

The study found that mice immunized with different formulations of the vaccine elicit high titers of antibodies that neutralize SARS-CoV-2 variants VIC31 (reference strain), Delta, and Omicron variants of coronavirus.

As per the study, there was an average 14.4-fold reduction in neutralization against the Omicron variant for one formulation of the Mynvax vaccine and a 16.5-fold reduction for another formulation, compared to VIC31.

Source-IANS


Advertisement